Inhibition of platelet aggregation by 1-methyl-4-phenyl pyridinium ion (MPP⁺) through ATP depletion: Evidence for the reduced platelet activities in Parkinson's disease

References

• Jankovic J. Parkinson's disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008; 79: 368–376
   PubMed Web of Science ®Google Scholar
• Di Monte DA, Lavasani M, Manning-Bog AB. Environmental factors in Parkinson's disease. Neurotoxicology 2002; 23: 487–502
   PubMed Web of Science ®Google Scholar
• Markey SP, Johannessen JN, Chiueh CC. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 1984; 311: 464–466
   PubMed Web of Science ®Google Scholar
• Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nature Protocols 2007; 2: 141–151
   PubMed Web of Science ®Google Scholar
• Dauer W, Przedborski S. Parkinson's disease: Mechanisms and models. Neuron 2003; 39: 889–909
   PubMed Web of Science ®Google Scholar
• Dunigan CD, Shamoo AE. Identification of the major transport pathway for the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. Neuroscience 1996; 75: 37–41
   PubMedGoogle Scholar
• Javitch JA, Uhl GR, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Characterization and localization of receptor binding sites in rat and human brain. Proc Natl Acad Sci USA 1984; 81: 4591–4595
   PubMedGoogle Scholar
• Greenamyre JT, Sherer TB, Betarbet R, Panov AV. Complex I and Parkinson's disease. IUBMB Life 2001; 52: 135–141
   PubMed Web of Science ®Google Scholar
• Parker WD, Jr, Parks JK, Swerdlow RH. Complex I deficiency in Parkinson's disease frontal cortex. Brain Res 2008; 1189: 215–218
   PubMed Web of Science ®Google Scholar
• Chinta SJ, Rajagopalan S, Butterfield DA, Andersen JK. In vitro and in vivo neuroprotection by gamma-glutamylcysteine ethyl ester against MPTP: Relevance to the role of glutathione in Parkinson's disease. Neurosci Lett 2006; 402: 137–141
   PubMedGoogle Scholar
• Urani C, Brambilla E, Santagostino A, Camatini M. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) affects the actin cytoskeleton and calcium level of Swiss 3T3 mouse fibroblasts. Toxicology 1994; 91: 117–126
   PubMedGoogle Scholar
• Del Zompo M, Bernardi F, Bonuccelli U, Maggio R, Bajorek M, Arnone M, Corsini GU. Properties of 3H-MPTP binding sites in human blood platelets. Life Sci 1986; 39: 1885–1891
   PubMedGoogle Scholar
• Andrews RK, Berndt MC. Platelet physiology and thrombosis. Thromb Res 2004; 114: 447–453
   PubMed Web of Science ®Google Scholar
• Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: Are we missing something?. Am J Med 2006; 119: 113–116
   PubMed Web of Science ®Google Scholar
• Bakken AM, Staeffler A, Jorgensen HA, Holmsen H. Glycerophospholipid molecular species in platelets and brain tissues–are platelets a good model for neurons?. Platelets 2006; 17: 484–492
   PubMed Web of Science ®Google Scholar
• Stahl SM, Meltzer HY. The human platelet as a model for the dopaminergic neuron: Kinetic and pharmacologic properties and the role of amine storage granules. Exp Neurol 1978; 59: 1–15
   PubMedGoogle Scholar
• Seyfert UT, Haubelt H, Vogt A, Hellstern P. Variables influencing multiplate whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets 2007; 18: 199–206
   PubMed Web of Science ®Google Scholar
• Bae ON, Kim YD, Lim KM, Noh JY, Chung SM, Kim K, Hong S, Shin S, Yoon JH, Chung JH. Salsolinol, an endogenous neurotoxin, enhances platelet aggregation and thrombus formation. Thromb Haemost 2008; 100: 52–59
   PubMedGoogle Scholar
• Griffith OW. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 1980; 106: 207–212
   PubMed Web of Science ®Google Scholar
• Chen ST, Chuang JI, Hong MH, Li EI. Melatonin attenuates MPP+-induced neurodegeneration and glutathione impairment in the nigrostriatal dopaminergic pathway. J Pineal Res 2002; 32: 262–269
   PubMed Web of Science ®Google Scholar
• Kim KA, Lee JY, Park KS, Kim MJ, Chung JH. Mechanism of menadione-induced cytotoxicity in rat platelets. Toxicol Appl Pharmacol 1996; 138: 12–19
   PubMedGoogle Scholar
• Sanchez A. Ca2+-independent secretion is dependent on cytoplasmic ATP in human platelets. FEBS Lett 1985; 191: 283–286
   PubMedGoogle Scholar
• Holmsen H, Robkin L. Effects of antimycin A and 2-deoxyglucose on energy metabolism in washed human platelets. Thromb Haemost 1980; 42: 1460–1472
   PubMedGoogle Scholar
• Korten A, Lodder J, Vreeling F, Boreas A, van Raak L, Kessels F. Stroke and idiopathic Parkinson's disease: Does a shortage of dopamine offer protection against stroke?. Mov Disord 2001; 16: 119–123
   PubMed Web of Science ®Google Scholar
• Sharma P, Nag D, Atam V, Seth PK, Khanna VK. Platelet aggregation in patients with Parkinson's disease. Stroke 1991; 22: 1607–1608
   PubMedGoogle Scholar
• Marttila RJ, Rinne UK. Arteriosclerosis, heredity, and some previous infections in the etiology of Parkinson's disease. A case-control study. Clin Neurol Neurosurg 1976; 79: 46–56
   PubMed Web of Science ®Google Scholar
• Mahaut-Smith MP, Ennion SJ, Rolf MG, Evans RJ. ADP is not an agonist at P2X(1) receptors: Evidence for separate receptors stimulated by ATP and ADP on human platelets. Br J Pharmacol 2000; 131: 108–114
   PubMedGoogle Scholar
• Grenegard M, Vretenbrant-Oberg K, Nylander M, Desilets S, Lindstrom EG, Larsson A, Ramstrom I, Ramstrom S, Lindahl TL. The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine. J Biol Chem 2008; 283: 18493–18504
   PubMedGoogle Scholar
• Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, De Feyter PJ, Specchia G, Ruzyllo W. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809–1840
   PubMed Web of Science ®Google Scholar
• Choi W-S, Kruse SE, Palmiter RD, Xia Z. Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat. Proc Natl Acad Sci USA 2008; 105: 15136–15141
   PubMedGoogle Scholar
• Lee WS, Tsai WJ, Yeh PH, Wei BL, Chiou WF. Divergent role of calcium on Abeta- and MPTP-induced cell death in SK-N-SH neuroblastoma. Life Sci 2006; 78: 1268–1275
   PubMedGoogle Scholar
• Absi E, Ayala A, Machado A, Parrado J. Protective effect of melatonin against the 1-methyl-4-phenylpyridinium-induced inhibition of Complex I of the mitochondrial respiratory chain. J Pineal Res 2000; 29: 40–47
   PubMedGoogle Scholar
• Oury C, Toth-Zsamboki E, Thys C, Tytgat J, Vermylen J, Hoylaerts MF. The ATP-gated P2X1 ion channel acts as a positive regulator of platelet responses to collagen. Thromb Haemost 2001; 86: 1264–1271
   PubMed Web of Science ®Google Scholar
• Fung CYE, Cendana C, Farndale RW, Mahaut-Smith MP. Primary and secondary agonists can use P2X1 receptors as a major pathway to increase cytoplasmic Ca2+ in the human platelet. J Thromb Haemost 2007; 5: 910–917
   PubMed Web of Science ®Google Scholar